Jaekwang Noh, Heewon Moon, Mina Hur, and Yeomin Yun
1. Plosker GL and Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59:323-89.
2. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, et al. Consensus document; therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995;17:606-14.
3. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004;77:1632-8.
4. Schambeck CM, Bedel A, Keller F. Limit of quantification (functional sensitivity) of the new IMx tacrolimus II microparticle enzyme immunoassay. Clin Chem 1998;44:
2217.
5. Taylor PJ, Jones A, Balderson GA, Lynch SV, Ross LG, Pond SM. Sensitive, specific quantitative analysis of Tacrolimus (FK506) in blood by liquid chromatography- electrospray tandem mass spectrometry. Clin Chem
1996;42:279-85.
6. Clinical and Laboratory Standards Institue. Evaluation of the Linearity of quantitative measurement procedures: A statistical approach; approved guideline. Document EP06-A.
Wayne, PA: Clinical and Laboratory Standards Institute, 2003.
7 Food and Drug Administration, Guidance for Industry on Bioanalytical Method Validation, Federal Register, vol. 66, no. 100, 23 May 2001.
8. Clinical and Laboratory Standards Institue. Evaluation of precision performance of quantitative measurement methods:
approved guideline. Document EP05-A2. Wayne, PA:
Clinical and Laboratory Standards Institute, 2004.
9. Clinical and Laboratory Standards Institue. Mass spectrometry in the clinical laboratory: General principles and guidance; Approved guideline. Document C50-A.
Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
10. Song SH, Jun SH, Park KU, Yoon Y, Lee JH, Kim JQ, et al. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:1331-8.
11. Clinical and Laboratory Standards Institue. Method comparison and bias estimation using patient samples;
Approved guidline. Document EP09-A2. Wayne, PA:
Clinical and Laboratory Standards Institute, 2002.
12. , , . Tacrolimus Sirolimus
. 2008;30:241-2.
13. Amstrong VW and Oellerich M. Critical evaluation of methods for therapeutic drug monitoring. In: Burton ME, ShawLM, et al. eds. Applied pharmacokinetics &
pharmacodynamics. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins, 2006:30-9.
14. Brown NW, Gonde CE, Adams JE, Trefger JM. Low hematocrit and serum albumin concentrations underlie the over estimation of Tacrolimus concentrations by microparticle enzymeimmunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem 2005;51:586-92.
15. Keevil BG, McCann SJ, Cooper DP, Morris MR. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2002;39:487-92.
16. Taylor PJ. Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. Ther Drug Monit 2004;26:215-9.
17. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantitation of three major immunosuppressant by liquid chromatography-tandem mass-spectrometry. Clin biochem 2001;34:285-90.
18. Cooper DP, Napoli KL, Taylor PJ. The MassTraktm reagent kit for tacrolimus quantification by HPLC-MS/MS: a multicentre validation. Ther Drug Monit. 2007;29:508-9.
